ATI CAPSTONE
PHARMACOLOGY ASSESSMENT
PRACTICE TEST 1
───────────────────────────────────────────────────────
40 Questions | Actual Latest Questions & 100% Verified Answers | Graded A+
Assessment Technologies Institute (ATI) Nursing Education
Comprehensive Pharmacological Competency Evaluation for NCLEX-RN Readiness
ATI Capstone Pharmacology / NGN-Aligned Format
NCSBN Clinical Judgment Measurement Model (CJMM)
Based on ATI Pharmacology Capstone Assessment Modules, NCSBN NCLEX-RN Test Plan (2023-
2026), standard pharmacology textbooks (Lehne, Rosenthal & Burchum), and clinical practice
guidelines (ACC/AHA, ADA, IDSA, APA, CDC).
, EXAM STRUCTURE & INTRODUCTION
This ATI Capstone Pharmacology Assessment Practice Test 1 format for 2026/2027 reflects the
standardized competency assessment administered by Assessment Technologies Institute (ATI) to
evaluate proficiency in pharmacological principles for pre-licensure nursing students completing
their capstone preparation. The Capstone Pharmacology Assessment denotes ATI's comprehensive
pharmacology evaluation designed to integrate foundational pharmacology knowledge with clinical
judgment skills aligned with the NCLEX-RN test plan and Next Generation NCLEX item types. The
exam measures knowledge of pharmacokinetic/pharmacodynamic concepts, medication
administration safety, system-specific drug classes (cardiovascular, respiratory, endocrine, CNS,
pain, infectious disease, GI), special population considerations, drug interaction recognition,
adverse effect monitoring, patient education strategies, and scenario-based clinical decision-
making using NGN-aligned item types. The standard ATI Capstone Pharmacology Assessment
Practice Test consists of approximately 40 multiple-choice and NGN-style questions covering these
critical pharmacology domains, designed to reinforce evidence-based medication management
practice and predict NCLEX-RN success.
Total Questions: 40 multiple-choice and Next Generation NCLEX-style questions
Question Types: Single-best-answer, SATA, Bowtie, Trend, Highlight, Matrix, Ordered Response,
and Scenario-based clinical decision-making items
Testing Time: Approximately 60-90 minutes (computer-based, proctored format via ATI Testing
platform)
Passing Score: Institution-specific benchmark (typically 75-85% equivalent or ATI scaled score
threshold)
Focus: Evidence-based pharmacotherapeutic principles, medication safety protocols, NCSBN
CJMM, and NGN standards
Remediation: ATI recommends structured remediation using Pharmacology Review Modules,
Active Learning Templates, and focused content review for items answered incorrectly
, Question 1 [Multiple Choice]
Domain: Pharmacokinetics & Pharmacodynamics
A nurse is caring for a patient who is malnourished and has low serum albumin (2.0
g/dL). The patient is prescribed warfarin 5 mg PO daily. Which effect should the
nurse anticipate related to the patient's albumin level?
A. Decreased therapeutic effect due to reduced warfarin absorption
B. Increased risk of bleeding due to higher levels of free (unbound) warfarin
C. No effect, as warfarin does not bind to plasma proteins
D. Increased warfarin excretion through the kidneys
Correct Answer: B. Increased risk of bleeding due to higher levels of free (unbound)
warfarin
Rationale: Warfarin is approximately 99% protein-bound, primarily to albumin. When serum
albumin is low (hypoalbuminemia), more warfarin remains in the free, pharmacologically active
form, increasing the anticoagulant effect and bleeding risk. This principle applies to all highly
protein-bound drugs (phenytoin, diazepam, digoxin). The nurse should monitor INR closely and
assess for signs of bleeding in malnourished patients receiving highly protein-bound medications.
──────────────────────────────────────────────────────────────
──────────────────
Question 2 [Select All That Apply (SATA)]
Domain: Pharmacokinetics & Pharmacodynamics
A nurse is reviewing a patient's medication list and notes the patient takes a CYP450
enzyme inducer (carbamazepine). Which of the following effects should the nurse
anticipate? (Select all that apply.)
A. Decreased serum levels of medications metabolized by the induced CYP450
enzymes
B. Increased risk of therapeutic failure for concurrently administered drugs
C. Increased serum levels of the inducing medication itself
D. Need for higher doses of medications metabolized by the same CYP450
pathway
E. Slower onset of action for all oral medications
Correct Answer: A. Decreased serum levels of medications metabolized by the
induced CYP450 enzymes; B. Increased risk of therapeutic failure for concurrently
administered drugs; D. Need for higher doses of medications metabolized by the
same CYP450 pathway
Rationale: CYP450 inducers (carbamazepine, phenobarbital, rifampin, St. John's wort) increase
the synthesis of metabolizing enzymes, accelerating the breakdown of co-administered drugs.
This reduces serum drug levels, potentially causing therapeutic failure. Dose increases may be
needed. Conversely, CYP450 inhibitors (ketoconazole, erythromycin, grapefruit juice) decrease
enzyme activity, raising drug levels and toxicity risk. This concept is critical for polypharmacy
management in NCLEX-RN preparation.
PHARMACOLOGY ASSESSMENT
PRACTICE TEST 1
───────────────────────────────────────────────────────
40 Questions | Actual Latest Questions & 100% Verified Answers | Graded A+
Assessment Technologies Institute (ATI) Nursing Education
Comprehensive Pharmacological Competency Evaluation for NCLEX-RN Readiness
ATI Capstone Pharmacology / NGN-Aligned Format
NCSBN Clinical Judgment Measurement Model (CJMM)
Based on ATI Pharmacology Capstone Assessment Modules, NCSBN NCLEX-RN Test Plan (2023-
2026), standard pharmacology textbooks (Lehne, Rosenthal & Burchum), and clinical practice
guidelines (ACC/AHA, ADA, IDSA, APA, CDC).
, EXAM STRUCTURE & INTRODUCTION
This ATI Capstone Pharmacology Assessment Practice Test 1 format for 2026/2027 reflects the
standardized competency assessment administered by Assessment Technologies Institute (ATI) to
evaluate proficiency in pharmacological principles for pre-licensure nursing students completing
their capstone preparation. The Capstone Pharmacology Assessment denotes ATI's comprehensive
pharmacology evaluation designed to integrate foundational pharmacology knowledge with clinical
judgment skills aligned with the NCLEX-RN test plan and Next Generation NCLEX item types. The
exam measures knowledge of pharmacokinetic/pharmacodynamic concepts, medication
administration safety, system-specific drug classes (cardiovascular, respiratory, endocrine, CNS,
pain, infectious disease, GI), special population considerations, drug interaction recognition,
adverse effect monitoring, patient education strategies, and scenario-based clinical decision-
making using NGN-aligned item types. The standard ATI Capstone Pharmacology Assessment
Practice Test consists of approximately 40 multiple-choice and NGN-style questions covering these
critical pharmacology domains, designed to reinforce evidence-based medication management
practice and predict NCLEX-RN success.
Total Questions: 40 multiple-choice and Next Generation NCLEX-style questions
Question Types: Single-best-answer, SATA, Bowtie, Trend, Highlight, Matrix, Ordered Response,
and Scenario-based clinical decision-making items
Testing Time: Approximately 60-90 minutes (computer-based, proctored format via ATI Testing
platform)
Passing Score: Institution-specific benchmark (typically 75-85% equivalent or ATI scaled score
threshold)
Focus: Evidence-based pharmacotherapeutic principles, medication safety protocols, NCSBN
CJMM, and NGN standards
Remediation: ATI recommends structured remediation using Pharmacology Review Modules,
Active Learning Templates, and focused content review for items answered incorrectly
, Question 1 [Multiple Choice]
Domain: Pharmacokinetics & Pharmacodynamics
A nurse is caring for a patient who is malnourished and has low serum albumin (2.0
g/dL). The patient is prescribed warfarin 5 mg PO daily. Which effect should the
nurse anticipate related to the patient's albumin level?
A. Decreased therapeutic effect due to reduced warfarin absorption
B. Increased risk of bleeding due to higher levels of free (unbound) warfarin
C. No effect, as warfarin does not bind to plasma proteins
D. Increased warfarin excretion through the kidneys
Correct Answer: B. Increased risk of bleeding due to higher levels of free (unbound)
warfarin
Rationale: Warfarin is approximately 99% protein-bound, primarily to albumin. When serum
albumin is low (hypoalbuminemia), more warfarin remains in the free, pharmacologically active
form, increasing the anticoagulant effect and bleeding risk. This principle applies to all highly
protein-bound drugs (phenytoin, diazepam, digoxin). The nurse should monitor INR closely and
assess for signs of bleeding in malnourished patients receiving highly protein-bound medications.
──────────────────────────────────────────────────────────────
──────────────────
Question 2 [Select All That Apply (SATA)]
Domain: Pharmacokinetics & Pharmacodynamics
A nurse is reviewing a patient's medication list and notes the patient takes a CYP450
enzyme inducer (carbamazepine). Which of the following effects should the nurse
anticipate? (Select all that apply.)
A. Decreased serum levels of medications metabolized by the induced CYP450
enzymes
B. Increased risk of therapeutic failure for concurrently administered drugs
C. Increased serum levels of the inducing medication itself
D. Need for higher doses of medications metabolized by the same CYP450
pathway
E. Slower onset of action for all oral medications
Correct Answer: A. Decreased serum levels of medications metabolized by the
induced CYP450 enzymes; B. Increased risk of therapeutic failure for concurrently
administered drugs; D. Need for higher doses of medications metabolized by the
same CYP450 pathway
Rationale: CYP450 inducers (carbamazepine, phenobarbital, rifampin, St. John's wort) increase
the synthesis of metabolizing enzymes, accelerating the breakdown of co-administered drugs.
This reduces serum drug levels, potentially causing therapeutic failure. Dose increases may be
needed. Conversely, CYP450 inhibitors (ketoconazole, erythromycin, grapefruit juice) decrease
enzyme activity, raising drug levels and toxicity risk. This concept is critical for polypharmacy
management in NCLEX-RN preparation.
